Immucell Corp
ICCC- Exchange
- Nasdaq
- Industry
- In Vitro & In Vivo Diagnostic Substances
- SEC CIK
- 0000811641
No open-market purchases or sales by Immucell Corp insiders were filed in the last 90 days; 31 institutions reported holding it in 13F filings for Q2 2026, worth $13.4M in total; no superinvestor holds it.
13F holders, Q1 2025
Institutional positions in Immucell Corp as of Mar 31, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 27
- 0 vs. Q4 2024
- Shares held
- 1.21M
- +3.53K (+0.3%) vs. Q4 2024
- Total value
- $5.79M
- −$418.0K (−6.7%) vs. Q4 2024
- New holders
- 0
- 7 more added
- Sold out
- 0
- 7 more reduced
Compare with Q4 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting ICCC on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 31 | $13.4M |
| Q1 2026 | 27 | $8.67M |
| Q4 2025 | 26 | $7.87M |
| Q3 2025 | 27 | $8.08M |
| Q2 2025 | 25 | $9.00M |
| Q1 2025 | 27 | $5.79M |
| Q4 2024 | 27 | $6.21M |
| Q3 2024 | 22 | $4.27M |
| Q2 2024 | 28 | $5.56M |
| Q1 2024 | 25 | $5.39M |
| Q4 2023 | 28 | $5.31M |
| Q3 2023 | 30 | $5.47M |
| Q2 2023 | 31 | $5.32M |
| Q1 2023 | 30 | $5.42M |
| Q4 2022 | 26 | $5.41M |
| Q3 2022 | 26 | $7.26M |
| Q2 2022 | 29 | $8.53M |
| Q1 2022 | 27 | $9.18M |
| Q4 2021 | 29 | $7.04M |
| Q3 2021 | 28 | $8.05M |
| Q2 2021 | 28 | $7.45M |
| Q1 2021 | 28 | $7.20M |
Institutions, Q1 2025
Shares, value and share of portfolio for each institution holding Immucell Corp; share changes are against Q4 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Capital Advisors, Ltd. LLC | 98 | $0 | 0.00% | −2−2.0% | Reduced |
| Wells Fargo & Company | 1 | $3 | 0.00% | 00.0% | Unchanged |
| JPMorgan Chase & Co | 10 | $48 | 0.00% | −1−9.1% | Reduced |
| Jones Financial Companies LLLP | 19 | $95 | 0.00% | 00.0% | Unchanged |
| Advisor Group Holdings, Inc. | 391 | $1.87K | 0.00% | 00.0% | Unchanged |
| Tower Research Capital LLC (TRC) | 1,017 | $4.87K | 0.00% | +211+26.2% | Added |
| Bank of America Corp | 2,087 | $10.0K | 0.00% | +2+0.1% | Added |
| HM Payson & Co | 4,000 | $19.2K | 0.00% | 00.0% | Unchanged |
| Essex Financial Services, Inc. | 11,000 | $52.7K | 0.00% | 00.0% | Unchanged |
| Mesirow Financial Investment Management, Inc. | 12,178 | $58.3K | 0.00% | −12,178−50.0% | Reduced |
| Susquehanna International Group, LLP | 13,501 | $64.7K | 0.00% | +1,897+16.3% | Added |
| BlackRock, Inc. | 14,130 | $67.7K | 0.00% | −273−1.9% | Reduced |
| Prosperity Planning, Inc. | 16,000 | $76.6K | 0.02% | 00.0% | Unchanged |
| UBS Group AG | 16,891 | $80.9K | 0.00% | +4,311+34.3% | Added |
| HighTower Advisors, LLC | 21,354 | $102.3K | 0.00% | 00.0% | Unchanged |
| Citadel Advisors LLC | 23,945 | $114.7K | 0.00% | −5,076−17.5% | Reduced |
| Strategic Financial Services, Inc, | 31,000 | $148.5K | 0.01% | 00.0% | Unchanged |
| Northern Trust Corp | 42,384 | $203.0K | 0.00% | −1,990−4.5% | Reduced |
| Shufro Rose & Co LLC | 61,028 | $292.3K | 0.02% | 00.0% | Unchanged |
| Dimensional Fund Advisors LP | 67,727 | $324.4K | 0.00% | +1,421+2.1% | Added |
| Geode Capital Management, LLC | 68,945 | $330.3K | 0.00% | +4,407+6.8% | Added |
| Morgan Stanley | 76,916 | $368.4K | 0.00% | +13,800+21.9% | Added |
| Bleichroeder LP | 101,594 | $486.6K | 0.13% | 00.0% | Unchanged |
| Dauntless Investment Group, LLC | 131,195 | $628.4K | 2.32% | 00.0% | Unchanged |
| Cresset Asset Management, LLC | 132,001 | $632.3K | 0.00% | 00.0% | Unchanged |
| Renaissance Technologies LLC | 133,989 | $641.8K | 0.00% | −3,000−2.2% | Reduced |
| Vanguard Group Inc | 225,595 | $1.08M | 0.00% | 00.0% | Unchanged |